<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117502">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01697969</url>
  </required_header>
  <id_info>
    <org_study_id>M-12-047</org_study_id>
    <nct_id>NCT01697969</nct_id>
  </id_info>
  <brief_title>Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients</brief_title>
  <official_title>Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to descriptively evaluate the corneal structures of allergic
      conjunctivitis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heidelberg Retina Tomograph (HRT) will be used to descriptively evaluate the corneal
      structures and assess the immune cell status of allergic conjunctivitis patients pre and
      post treatment with olopatadine 0.2% in relation to a normative database.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Patient-Assessed Ocular Itching</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>As rated by the patient on a 0-4 scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-Assessed Ocular Itching</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>As rated by the patient on a 0-4 scale.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Pataday</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of olopatadine 0.2% once daily in both eyes for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine hydrochloride ophthalmic solution, 0.2%</intervention_name>
    <description>One drop once daily in both eyes for 14 days</description>
    <arm_group_label>Pataday</arm_group_label>
    <other_name>PATADAYÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Read, sign, and date an Ethics Committee reviewed and approved informed consent form.

          -  Females of childbearing potential who:

               -  Are not breast-feeding;

               -  Do not intend to become pregnant for the duration of the study;

               -  Are using adequate birth control methods and agree to continue for the duration
                  of the study.

          -  Able to read, understand and answer questions by investigator.

          -  Willing and able to attend all required study visits and follow directions as
             stipulated by the protocol and investigator.

          -  History of allergic conjunctivitis (within the past 12 months) and active signs and
             symptoms of ocular allergies for which treatment is necessary, in the opinion of the
             investigator.

          -  Visual acuity correctable to 20/30 (Snellen) or better in each eye at distance with
             or without glasses correction.

          -  Ocular health within normal limits as determined by the investigator.

          -  No contact lens wear 14 days prior to enrollment and willing to not wear contact
             lenses for the duration of the study.

          -  Willing to follow a 14-day washout period due to contraindicated medication use, if
             deemed necessary by investigator.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Contraindications or hypersensitivity to the use of the test article or its
             components.

          -  Inability or unwillingness to follow all study instructions and complete study visits
             as required.

          -  Only one sighted eye or visual acuity not correctable to 20/30 (Snellen) in both eyes
             at the Screening Visit.

          -  Ocular trauma within 6 months prior to Visit 1 in either eye.

          -  Any ocular surgical intervention within six months prior to Visit 1 or anticipation
             of ocular surgery during the study.

          -  Presumed or actual ocular infection within 30 days prior to Visit 1.

          -  Any severe or serious ocular condition or significant illness.

          -  Any abnormal slit-lamp findings at the time of the Screening Visit.

          -  Contact lens wear within 14 days prior to the study start and unwillingness to
             undergo a wash-out period of 14 days; unwilling to not wear contact lenses for the
             duration of the study.

          -  Use of over-the-counter (OTC) ocular medications within the past 14 days unless
             willing to follow wash out period.

          -  Use of topical or systemic ocular medications requiring longer than a two-week
             washout period.

          -  Participation in any other investigational study in the 30-day period before entry
             into this study (i.e., Visit 1) or concomitantly with this study.

          -  Women who are pregnant, nursing, or of childbearing potential not utilizing adequate
             birth control measures.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Sindt, OD, FAAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pam Kaur, MS PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 26, 2013</lastchanged_date>
  <firstreceived_date>September 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allergic conjunctivitis</keyword>
  <keyword>Pataday</keyword>
  <keyword>Olopatadine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Olopatadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
